June 2013
Volume 54, Issue 15
ARVO Annual Meeting Abstract  |   June 2013
Comparison of two rodent models of dry eye induced by Scopolamine
Author Affiliations & Notes
  • Pierre-Paul Elena
    Iris Pharma, La Gaude, France
  • Nicolas Cimbolini
    Iris Pharma, La Gaude, France
  • Sophie Antonelli
    Iris Pharma, La Gaude, France
  • Laurence Feraille
    Iris Pharma, La Gaude, France
  • Stefano Barabino
    Clinica Oculistica, Genova, Italy
  • Philippe Margaron
    Iris Pharma, La Gaude, France
  • Footnotes
    Commercial Relationships Pierre-Paul Elena, None; Nicolas Cimbolini, None; Sophie Antonelli, None; Laurence Feraille, None; Stefano Barabino, None; Philippe Margaron, Iris Pharma (E)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 6002. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Pierre-Paul Elena, Nicolas Cimbolini, Sophie Antonelli, Laurence Feraille, Stefano Barabino, Philippe Margaron; Comparison of two rodent models of dry eye induced by Scopolamine. Invest. Ophthalmol. Vis. Sci. 2013;54(15):6002.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: Dry eye syndrome is a relatively common disease with multifactorial causes. It is necessary to have an experimental model to test and select therapeutic candidates for this disease. Here we compare two experimental models using scopolamine, a tropane alkaloid drug with muscarinic antagonist effects, to suppress lacrymation and induce dry eye symptoms.

Methods: The first experimental model consisted in inducing dry eye in albino rats by systemic and continuous delivery of scopolamine (20mg/day) via osmotic pumps implanted subcutaneously on Day 1. Animals were divided in three groups of five rats: In the first group the pumps delivered saline solution. The second and the third groups the pumps delivered 20 mg/day of scopolamine solution over 21 days. The second experimental model consisted in placing pigmented mice in a controlled environmental chamber (relative humidity <25%, air-flow 15L/min, temperature 20-22°C). Mice received transdermal patches of scopolamine (0.5 mg/72h) every 3 days. Animals were divided in three groups of five mice: the first group was placed in normal environmental condition (relative humidity >55%, temperature 20-22°C) without transdermal scopolamine administration. The second and the third groups were placed in the controlled environmental chamber with transdermal scopolamine administration. For both models, the first two groups received saline instillation and the third group, 0,05% cyclosporine eye drops. Tear production was measured with the phenol red thread (PRT) test and the corneal defects were examined by slit-lamp observation. These examinations were preformed at baseline and on day 7 for the mouse and rat models, and on days 14 et 21 only for rat model in both eyes.

Results: Symptoms of dry eye, including decrease in tear secretion, appearance of corneal defects and a rise in the inflammatory markers investigated, were observed in both rat and mouse models. Moreover these symptoms decreased after treatment with topical cyclosporine, a drug used in dry eye.

Conclusions: Scopolamine treated rats and combination of scopalamine treatment and controlled environment in mice, are therefore valuable models to mimic human dry eye syndrome.

Keywords: 486 cornea: tears/tear film/dry eye • 637 pathology: experimental • 421 anterior segment  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.